Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3869-3878

  Kobayashi, Hiroya ^a,b   Nagato, Toshihiro ^a   Oikawa, Kensuke ^a   Sato, Keisuke ^a   Kimura, Shoji ^a   Aoki, Naoko ^a   Omiya, Ryusuke ^b   Tateno, Masatoshi ^a   Celis, Esteban ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; EPITOPE; HLA ANTIGEN CLASS 2; HLA DR1 ANTIGEN; HLA DR13 ANTIGEN; HLA DR15 ANTIGEN; HLA DR53 ANTIGEN; HLA DR9 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOCHONDRIAL PROTEIN; PROTEIN TARP; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CELL LINE; CELL SPECIFICITY; CELL STIMULATION; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED;

EID: 18844388681     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2238     Document Type: Article

References (32)

1. Jermal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. van der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64.
3. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature (Lond) 2001;411:380-4.
4. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
5. Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300.
6. + prostate cancer patients. Prostate 2003;57:152-9.
7. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62:5807-12.
8. + cytotoxic T lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptides. Prostate 1998;36:129-38.
9. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000;60:5522-8.
10. Francini G, Scardino A, Kosmatopoulos K, et al. High-affinity HLA-A*0201 peptides from parathyroid hormone-related protein generated in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 2002;169:4840-9.
11. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor γ chain locus. Proc Natl Acad Sci U S A 2000;97:9437-42.
12. Maeda H, Nagata S, Wolfgang CD, et al. The T cell receptor chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria. J Biol Chem 2004;279:24561-8.
13. Oh S, Terabe M, Pendleton CV, et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004;64:2610-8.
14. Carlsson B, Totterman TT, Essand M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 2004;61:161-70.
15. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
16. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
17. Giuntoli RL II, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper Tcells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002;8:922-31.
18. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 2001;61:7577-84.
19. + T cells specific for an MHC class II promiscuous epitope. J Immunol 2002;169:2172-9.
20. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25.
21. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001;61:4773-8.
22. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000;60:5228-36.
23. Kobayashi H, Omiya R, Sodey B, et al. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res 2003;9:5386-93.
24. + helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res 2004;10:7053-62.
25. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-73.
26. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
27. + T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 2003;171:219-25.
28. Hural JA, Friedman RS, McNabb A, et al. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol 2002;169:557-65.
29. Schroers R, Shen L, Rollins L, et al. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 2003;9:3260-71.
30. + T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-96.
31. Viner NJ, Nelson CA, Deck B, Unanue E. Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol 1996;156:2365-8.
32. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue E. A single MHC anchor residue alters. the conformation of a peptide-MHC complex inducing T cells that survive negative selection. J Immunol 2001;166:5874-7.